| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/2000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Gamma-enolase, 2-phospho-D-glycerate hydro-lyase, Enolase 2, Neural enolase, Neuron-specific enolase, NSE, ENO2 |
| Entrez GeneID | 2026 |
| WB Predicted band size | 47.3kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This ENOG monoclonal antibody is generated from mouse immunized with ENOG recombinant protein. |
| Formulation | Purified antibody in TBS with 0.05% sodium azide. |
+ +
以下是关于ENOG(α-烯醇化酶，ENO1)抗体的3篇代表性文献摘要，涵盖其在疾病诊断及机制研究中的应用：
---
1. **文献名称**：*Autoantibodies to ENO1 in systemic lupus erythematosus: potential role in inflammation and vascular damage*
**作者**：Muller et al.
**摘要**：本研究探讨了系统性红斑狼疮(SLE)患者血清中抗ENO1抗体的水平及其与疾病活动的相关性。研究发现，抗ENO1抗体可通过激活补体通路加剧血管内皮炎症，提示其可能参与SLE的血管病变机制。
2. **文献名称**：*ENO1 as a serum biomarker for early detection of non-small cell lung cancer*
**作者**：Wang et al.
**摘要**：通过ELISA检测非小细胞肺癌(NSCLC)患者血清中的ENO1抗体水平，发现其敏感性和特异性优于传统标志物CEA，表明抗ENO1抗体可能作为NSCLC早期诊断的非侵入性生物标志物。
3. **文献名称**：*Anti-ENO1 antibodies promote tumor cell invasion via extracellular matrix remodeling in pancreatic cancer*
**作者**：Garcia et al.
**摘要**：该研究揭示抗ENO1抗体通过上调基质金属蛋白酶(MMPs)表达，促进胰腺癌细胞外基质降解，从而增强肿瘤侵袭性，为靶向ENO1的抗体干预提供了理论基础。
---
注：以上内容基于α-烯醇化酶(ENO1)抗体的典型研究方向虚构，实际文献需通过学术数据库检索确认。若需具体文献，建议使用关键词“ENO1 antibody”或“alpha-enolase autoantibody”在PubMed或Web of Science中查找。
**Background of ENO1 (Alpha-Enolase) Antibodies**
ENO1 antibodies target alpha-enolase, a glycolytic enzyme encoded by the *ENO1* gene. Alpha-enolase catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate in glycolysis but also exhibits non-glycolytic functions, including roles in hypoxia response, cell adhesion, and immune regulation. It localizes intracellularly but can surface-translocate under stress, acting as a receptor for plasminogen and pathogens, which links it to infectious and autoimmune pathologies.
In autoimmune diseases, anti-ENO1 antibodies are detected in conditions like systemic lupus erythematosus (SLE) and rheumatoid arthritis, where molecular mimicry or post-translational modifications may trigger autoimmunity. In cancer, ENO1 is overexpressed in malignancies such as lung, pancreatic, and breast cancers, promoting tumor growth, metastasis, and immune evasion. Autoantibodies against ENO1 in cancer patients may reflect immune surveillance attempts or tumor-associated antigen release.
ENO1 antibodies also have diagnostic relevance. For instance, anti-ENO1 antibodies in infectious endocarditis correlate with *Streptococcus* infections, while in autoimmune encephalitis, they serve as paraneoplastic markers. Research continues to explore their therapeutic potential, including antibody-targeted therapies and cancer vaccines. However, their dual role as both pathogenic drivers and protective biomarkers underscores the complexity of ENO1’s immunobiology, necessitating context-specific interpretation in clinical settings.
×
